Genuine acute autoimmune hepatitis has better therapeutic response and prognosis
- 4 January 2026
- journal article
- research article
- Published by Springer Nature in Hepatology International
- Vol. 20 (2) , 342-352
Abstract
Background and aim Heterogeneous diagnostic criteria for acute autoimmune hepatitis (AIH) across studies hinder the characterization of genuine acute AIH. We developed stringent and multidimensional criteria to distinguish acute, acute-on-chronic, and chronic autoimmune hepatitis (A-AIH, AC-AIH, and C-AIH), aiming to elucidate their clinical profiles. Methods We consecutively enrolled patients diagnosed with definite AIH between 2012 and 2024. All patients were stratified using stringent criteria encompassing onset time (A-AIH: < 6 months), acute presentation (total bilirubin (TB) ≥ 5 mg/dL or alanine aminotransferase (ALT)/aspartate aminotransferase (AST) ≥ 10 × upper limits of normal (ULN)), imaging evidence of cirrhosis, and histological fibrosis stage (A-AIH: fibrosis stage ≤ 1). Clinical features and treatment responses were compared across the three groups. Results Among 235 patients, 10.6% were classified as A-AIH, 57.9% as AC-AIH, and 31.5% as C-AIH, with a median follow-up of 51.9 (IQR 21.8–78.8) months. The cumulative full biochemical remission (FBR) rate was 92.0% in A-AIH, 75.7% in AC-AIH, and 59.5% in C-AIH (p = 0.003). The median FBR times were 2.9, 5.5, and 14.5 months, respectively (p = 0.002). Liver-related mortality rates were 0%, 8.8%, and 16.2% across the three groups (p = 0.021). Cirrhosis and albumin (ALB) levels were independent predictors of FBR, and ALB was also independently associated with liver-related death. Conclusion Patients with A-AIH achieved the highest cumulative FBR rate, whereas those with C-AIH had the poorest treatment response and the highest liver-related mortality. Graphical abstractKeywords
Funding Information
- the 135 Project for Disciplines of Excellence, West China Hospital, Sichuan University (No. ZYGD23031)
- Sichuan Science and Technology Program (No. 2023NSFSC1618)
This publication has 23 references indexed in Scilit:
- Acute presentation of autoimmune hepatitis –from acute hepatitis to ALF and ACLF-Hepatology International, 2024
- Outcomes of patients with acute severe autoimmune hepatitis: Predictors of non‐response to corticosteroids and need for liver transplantationUnited European Gastroenterology Journal, 2024
- Clinical, biochemical and histological features related to treatment response and prognosis in autoimmune hepatitisAnnals of Hepatology, 2024
- Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis GroupJournal of Hepatology, 2022
- Second-line and third-line therapy for autoimmune hepatitis: A position statement from the European Reference Network on Hepatological Diseases and the International Autoimmune Hepatitis GroupJournal of Hepatology, 2020
- Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver DiseasesHepatology, 2019
- Clinical and prognostic implications of acute onset of Autoimmune Hepatitis: An Italian multicentre studyDigestive and Liver Disease, 2018
- Long-term observation of acute-onset autoimmune hepatitis presenting clinically and radiologically as acute hepatitisHepatology International, 2018
- Rapidity of treatment response and outcome in type 1 autoimmune hepatitisJournal of Hepatology, 2009
- Simplified criteria for the diagnosis of autoimmune hepatitis†Hepatology, 2008